Carlos Iribarren to Omalizumab
This is a "connection" page, showing publications Carlos Iribarren has written about Omalizumab.
Connection Strength
1.166
-
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials. J Allergy Clin Immunol. 2017 05; 139(5):1678-1680.
Score: 0.575
-
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma. J Allergy Clin Immunol. 2017 May; 139(5):1489-1495.e5.
Score: 0.561
-
Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014 Sep; 134(3):560-567.e4.
Score: 0.030